Clinical Trials Browser

INDUSTRY × Has results × Fulvestrant × Clear all

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis, Neoplasms

Advanced Metastatic Breast Cancer

Breast Cancer Metastatic

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms, Neoplasms

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

Hormone Receptor Positive Breast Cancer

Breast Neoplasms

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

Advanced Cancer

Breast Neoplasms, Neoplasms

Lymphoma, Non-Hodgkin

Advanced Breast Cancer

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

Lethal Congenital Contracture Syndrome 2

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Neoplasms

Breast Neoplasms

Breast Neoplasms

Solid Malignancies

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Advanced Breast Cancer

Breast Neoplasms

Advanced Breast Cancer

Clinical Trials

CONFIRM

VERITAC-2

INAVO120

FALCON

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

AMEERA-3

MONARCH plus

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

postMONARCH

BYLieve

A Study of TAS-120 in Patients With Metastatic Breast Cancer

MORPHEUS HR+BC

MONARCH 2

EMERALD

EMBER-3

B-PRECISE-01

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

SOLAR-1

monarcHER

IPATunity150

EPIK-B4

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

TELEPIK

SUMMIT

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

MONALEESA-3

MK-4440-001

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

SANDPIPER

Veronica

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

SHERBOC

BELLE-2

FINDER II

Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

14C

BELLE-3

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

ZACFAST

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor